Matthew B. Frankel
Chief Tech/Sci/R&D Officer chez CHEMOMAB THERAPEUTICS LTD.
Fortune : - $ au 31/03/2024
Profil
Matthew B.
Frankel is currently the Chief Medical Officer & VP-Drug Development at Chemomab Therapeutics Ltd.
Prior to this, he worked as the VP-Clinical Development & Medical Affairs at Boehringer Ingelheim Pharmaceuticals, Inc. from 2018 to 2022.
He received his undergraduate degree from Vassar College, his doctorate from David Geffen School of Medicine, and his MBA from Kellogg School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Matthew B. Frankel
| Sociétés | Poste | Début |
|---|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Chief Tech/Sci/R&D Officer | 14/11/2022 |
Anciens postes connus de Matthew B. Frankel
| Sociétés | Poste | Fin |
|---|---|---|
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Chief Tech/Sci/R&D Officer | 01/11/2022 |
Formation de Matthew B. Frankel
| Vassar College | Undergraduate Degree |
| David Geffen School of Medicine | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CHEMOMAB THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
